The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
Official Title: Real-world Study for the Safety of Albumin-Bound Paclitaxel in Malignant Tumors
Study ID: NCT04060290
Brief Summary: This is a multi-center, Prospective, observational study,to evaluate the safety and influencing factors of albumin-bound paclitaxel in the real-world chinese population,and evaluate of the efficacy of albumin-bound paclitaxel in patients with malignant tumors and its impact on quality of life.
Detailed Description:
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Anhui Cancer Hospital, Hefei, Anhui, China
Maanshan People's Hospital, Maanshan, Anhui, China
Hainan General Hospital, Haikou, Hainan, China
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Henan Cancer Hospital, Zhengzhou, Henan, China
Inner Mongolia Autonomous Region Cancer Hospital, Hohhot, Inner Mongolia Autonomous Region, China
Liaoning Cancer Hospital, Shenyang, Liaoning, China
Zhongshan Hospital, Shanghai, Shanghai, China
Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shanxi, China
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, , China
Name: Wei Zhao
Affiliation: Shiyao Group Ouyi Pharmaceutical Co., Ltd.
Role: STUDY_DIRECTOR